GenSight Biologics raises nearly €1.7 million in a successful funding round led by Heights Capital, Invus, and UPMC Enterprises to advance its gene therapies.
Amount Raised
€1.69 Million
Round Type
Post-IPO Equity
ParisBiotechnologyHealth CareTherapeuticsBiopharmaInvestors
Description
GenSight Biologics announced the successful completion of a €1.7 million fundraising, subscribed by Heights Capital, Invus, and UPMC Enterprises. This funding aims to extend cash runway and facilitate the RECOVER Phase III trial. The company focuses on gene therapies for retinal diseases and CNS disorders. This round follows previous successful fundraisings totaling over €10 million in the past year.
Quick answer
GenSight Biologics raised €1.69 Million in a Post-IPO Equity round, dated March 10, 2026. Investors: Heights Capital, Invus and UPMC Enterprises. GenSight Biologics is based in Paris, Ile-de-France, France.
- How much did GenSight Biologics raise?
- GenSight Biologics raised €1.69 Million in a Post-IPO Equity round on March 10, 2026.
- Who invested in GenSight Biologics?
- Heights Capital, Invus and UPMC Enterprises are named as investors in this round.
- What does GenSight Biologics do?
- GenSight Biologics is a clinical-stage biotechnology company discovering and developing novel therapies for neurodegenerative retinal diseases and diseases of the central nervous system.
- Where is GenSight Biologics based and how big is it?
- GenSight Biologics is based in Paris, Ile-de-France, France. Fundz records about 26 employees.
- Who are the decision-makers at GenSight Biologics?
- Fundz holds 4 contacts at GenSight Biologics, including the Chief Technology Officer. Names and contact details are shown to Fundz members.
Source: Fundz verified event record.
Who else raised in Therapeutics and Biopharma around the same time
Companies in the same sectors as GenSight Biologics that raised within 45 days of this round, from Fundz verified event records.
- Lighthouse Pharmaceuticals raised $15M (Series A) on April 22, 2026.
- Sparian Biosciences raised $15M (Grant) on April 13, 2026.
- Sidewinder Therapeutics raised $137M (Series B) on April 8, 2026.
- Denali Therapeutics raised $200M (Debt Financing) on March 31, 2026.
- Tempest Therapeutics raised $2M on March 20, 2026.
- VST BIO Corporation raised an undisclosed amount (Series A) on March 17, 2026.
Who to call at GenSight Biologics, and when
A new round usually means GenSight Biologics is about to hire and buy. The teams that reach out first get the meeting.
- An alert the day GenSight Biologics raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at GenSight Biologics, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at GenSight Biologics. With Fundz connected, it knows.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment GenSight Biologics raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
Related People
GenSight Biologics raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.